Table 5.
Total number of studies | Total number of subjects | Pooled prevalence (95% CI) [%] |
Cochrane’s Q | I2 (95% CI) [%] | p value | |
---|---|---|---|---|---|---|
Anterior to M2a | 2 | 284 | 3.3 (0.5–20.3) | 6.67 | 85.0 (58.5–94.6) | p = 0.0098 |
Opposite M2b | 33 | 8852 | 5.0 (3.2–3.9) | 371.78 | 91.4 (89.0–93.3) | p < 0.0001 |
Africa | 4 | 980 | 6.2 (1.0–30.0) | 10.86 | 72.4 (48.5–93.3) | p = 0.0045 |
Asia | 23 | 4731 | 3.8 (2.2–6.3) | 160.52 | 86.3 (80.9–90.7) | p < 0.0001 |
Europe | 2 | 2800 | 16.0 (9.9–26.9) | 3.68 | 72.8 (30.3–89.4) | p = 0.055 |
South America | 2 | 162 | 4.3 (2.2–9.6) | 1.05 | 5.0 (0.0–11.4) | p = 0.30 |
Between M2 and M3 | 37 | 9496 | 19.3 (15.3–24.0) | 547.71 | 94.5 (93.2–95.6) | p < 0.0001 |
Africa | 4 | 980 | 11.4 (2.9–35.6) | 54.62 | 96.3 (92.5–98.2) | p < 0.0001 |
Asia | 27 | 5366 | 20.6 (17.3–24.4) | 155.95 | 86.5 (81.0–90.5) | p < 0.0001 |
Europe | 3 | 2907 | 11.8 (5.9–22.1) | 21.87 | 90.9 (77.5–96.3) | p < 0.0001 |
South America | 2 | 222 | 18.1 (2.1–69.6) | 32.83 | 97.0 (92.9–98.7) | p < 0.0001 |
Opposite M3 | 38 | 9754 | 64.9 (58.7–70.7) | 610.61 | 94.8 (93.5–95.8) | p < 0.0001 |
Africa | 4 | 980 | 49.5 (46.4–52.6) | 76.94 | 97.4 (95.0–98.6) | p < 0.0001 |
Asia | 27 | 5366 | 66.7 (65.4–67.9) | 363.88 | 94.0 (92.4–95.6) | p < 0.0001 |
Europe | 3 | 2907 | 74.7 (73.1–76.2) | 0.21 | 0.0 | p = 0.90 |
South America | 3 | 322 | 65.8 (60.5–70.8) | 33.96 | 94.1 (86.7–97.4) | p < 0.0001 |
Distal to M3 | 31 | 8608 | 6.0 (3.7–9.6) | 1183.69 | 96.7 (96.1–97.3) | p < 0.0001 |
Asia | 24 | 4841 | 7.7 (7.0– 8.6) | 263.34 | 89.0 (84.5–92.2) | p < 0.0001 |
Europe | 3 | 2907 | 2.4 (1.9–3.0) | 10.93 | 81.7 (49.2–93.4) | p = 0.0042 |
South America | 2 | 260 | 25.8 (20.8–31.4) | 26.11 | 96.2 (90.7–98.4) | p < 0.0001 |